Probiotic Delivery Technology Awarded Patent In China

The Chinese Patent Office has issued Nutraceutix, patent no 02823678.5 for BIO-tract. The company said that the technology has been awarded based on BIO-tract’s ability to protect sensitive ingredients such as probiotic organisms from stomach acid on their way to optimal release sites in the intestinal tract.

BIO-tract products overcome the three major barriers to effective probiotic supplementation: Survival of beneficial, but fragile organisms through the manufacturing process; Survival on the store shelf over extended timeframes, even at room temperature; Survival past harsh stomach acids that denature unprotected probiotic organisms.

Once ingested, BIO-tract tablets quickly form a protective layer, which shields probiotic organisms from the acidic conditions of the stomach. After passing from the stomach to the intestinal tract, the tablets release the organisms at optimal rates determined by formulation.

The company said that application of the BIO-tract delivery system is not limited to probiotics. It has been applied to many other ingredients that benefit from effective gastric acid protection, buffering, controlled release and once-daily dosing. For nutraceuticals, BIO-tract offers modifiable release rates ranging from just a few hours to all day long.

Steve Moger, president and CEO of Nutraceutix, said: “Years ago, we recognised the need for an effective probiotic and nutraceutical delivery technology – one that draws upon proven pharmaceutical principles, yet is economically feasible in the nutritional supplement marketplace. Our research and development investments in BIO-tract continue to be validated by yet another key patent.”

Randy Schoenfeldt, SVP of Nutraceutix, said: “This latest patent is particularly significant due to the enormous size and potential of the market in China.”